Navigation Links
Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
Date:10/30/2008

SAN DIEGO, Oct. 30 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostics company, announced that the U.S. Patent and Trademark Office (USPTO) has issued two separate patents covering the technology for PROMETHEUS(R) Thiopurine Metabolites, a diagnostic test that enables physicians to optimize ongoing dosing of thiopurines to reach and maintain desired therapeutic levels. The USPTO has approved the issuance of the claims in U.S. Patent Nos. 7,425,546 and 7,429,570, both entitled, "Methods of optimizing drug therapeutic efficacy for treatment of immune- mediated gastrointestinal disorders."

"We are pleased that the USPTO has acknowledged the validity of these patents and approved their issuance," said William Franzblau, Vice President of Legal Affairs for Prometheus. "This is another example of our ongoing commitment to growing our substantial intellectual property portfolio, which we believe is a key competitive advantage. In addition, we will continue to protect and vigorously enforce our proprietary rights, if necessary."

PROMETHEUS(R) Thiopurine Metabolites helps keep patients' drug metabolite levels within an optimal therapeutic range, thereby increasing the probability of a positive response and potentially reducing the need for other medications. Thiopurine metabolites testing helps identify some of the reasons for treatment failure and monitor for potential toxicity before it occurs.

Combined, Prometheus' thiopurine management diagnostic tests - PROMETHEUS(R) TPMT Genetics and PROMETHEUS(R) TPMT Enzyme for individualizing dosing before therapy, and PROMETHEUS(R) Thiopurine Metabolites for optimizing dosing during therapy - provide information that helps physicians better manage therapeutic treatment, achieve better clinical outcomes and lower the potential for toxicity.

About Thiopurines

Thiopurines are a class of drugs that include azathioprine and mercaptopurine. These drugs are ind
'/>"/>

SOURCE Prometheus Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Prometheus Licenses COLAL-PRED(R) From Alizyme
2. Medpace Strengthens Presence in Central Europe
3. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
4. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
5. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
6. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
7. Anavex strengthens Board of Directors
8. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. JobLoft.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
11. BioSpace.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in ... where to do so would constitute a violation of the ... or the "Company") (LSE: SHP, NASDAQ: SHPG ) ... held a meeting with representatives of AbbVie. This ... or approval of AbbVie. A further update will ...
(Date:7/11/2014)... 11, 2014 BCC Research ( http://www.bccresearch.com ... POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the ... reached nearly $140 billion in 2013. This is estimated ... five-year compound annual growth rate (CAGR) of 28.6%. , ... interesting and exciting possibilities within the broader PCR field. ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/11/2014)... Cayenne Medical, Inc., a privately ... soft tissue reconstruction segment, announced the worldwide launch ... involving the shoulder and extremities. The SureLock System ... deployment method. The unique delivery eliminates manual tensioning ... or anchor displacement (also commonly know as anchor ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... Emisphere Technologies, Inc.,(Nasdaq: EMIS ), a biopharmaceutical ... therapeutic molecules using its eligen(R) technology,today announced that the ... on February 12, 2008 at the Waldorf Astoria Hotel ... Chief Executive Officer of,Emisphere, will present for the company ...
... Feb. 4 Pfizer,s loss of some top,talent, ... gain of two,Michigan companies teaming to help speed ... metastatic bone disease, rheumatoid arthritis and,osteoporosis., Velcura ... announced,his biotechnology company will work with Dr. Sliskovic ...
... Number of ... Patients, MALVERN, Pa., Feb. 4 Johns Hopkins ... in the United,States to install the newest magnetic resonance ... -- the,MAGNETOM(R) Verio. Combining 3 Tesla (T) strength and ...
Cached Biology Technology:Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12 2Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease 2Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio 2Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio 3
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... demonstrated that transplantation of mesenchymal stem cells can stimulate ... models of Alzheimer,s disease (AD) and improve tissue and ... studies are reported on the therapeutic effect of adipose-derived ... on the effect on oxidative injury and neurogenesis in ... her team, School of Life Sciences, Tsinghua University, China ...
(Date:7/11/2014)... -- Research and Markets has announced the ... Industry Analysis Size Share Growth Trends and Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 The rising number ... for high level security in both private and public ... username and passwords, tokens etc. are vulnerable to attacks. ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... has provided new insight into the consequence of ... Prion and Alzheimer,s disease. Prion and Alzheimer,s ... mutations, or more commonly, interactions between an individual,s ... neurons to become misfolded or misrouted. In these ...
... have bacteria in their guts that may predispose them to ... University of California, Berkeley, and the University of Arizona, Tucson. ... than a thousand people from around the world showed that ... have been linked to obesity than did people living farther ...
... have shifted over the past 4 to 6 years, ... rose to the fore. Scientists who are leading advisors ... examine the state-of-the-science in "Research Challenges in Climate Change: ... 14 at the American Association for the Advancement of ...
Cached Biology News:New insight into protein misfolding in neurodegenerative disorders 2Geographic variation of human gut microbes tied to obesity 2Geographic variation of human gut microbes tied to obesity 3Hot issues in climate change research to be debated at AAAS Annual Meeting 2
... DMW143 taken from the SMZ line is a ... production and testing. It is available with a ... or a space-saving compact base (N2GG). This microscope ... and a projector all at the same time ...
... , Automatic grid, subgrid and spot finding overcome ... template assignment , ... Extensive background and signal options to optimize, ... results , Characterize more precisely ...
This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
... contains 400 unique human proteins on ... The proteins, a cross section of ... quadruplicate for high-quality results. Additional control ... guarantee high validity and reproducibility., ,UNIchip ...
Biology Products: